Inhibition of hepatic fibrogenesis by matrix metalloproteinase‐9 mutants in mice
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Tissue inhibitor of metalloproteinases‐1 (TIMP‐1) plays a crucial role in the pathogenesis of hepatic fibrosis and thus may represent an important therapeutic target in the design of anti‐fibrotic strategies for chronic liver disease. We present an innovative therapy based on the assignment of inactivated enzymes acting as scavengers for TIMP‐1. Hepatic fibrosis was induced in BALB/c mice by repetitive intraperitoneal CCl 4 injection. The animals were treated with proteolytic inactive matrix metalloproteinase‐9 mutants (E402Q, H401A, E402H/H411E) using adenovirus‐mediated gene transfer. Application of these MMP‐9 mutants inhibited fibrogenesis, which was indicated by decreasing portal and periportal accumulation of collagen. Total hydroxyproline of liver tissue, the morphometric stage of fibrosis as well as mRNA expression of marker proteins for hepatic fibrosis in livers of E402Qand H401A‐treated mice were significantly reduced. MMP‐9 mutants suppressed transdifferentiation of hepatic stellate cells to the myofibroblast like phenotype in vitro and in vivo. Moreover, adenoviral application of the mutants MMP‐9‐H401A and ‐E402Q led to increased apoptosis of activated hepatic stellate cells, thought to be the main promoters of hepatic fibrosis. Application of MMP‐9 mutants as TIMP‐1 scavengers may provide a new therapeutic strategy for hepatic fibrosis.—Roderfeld, M., Weiskirchen, R., Wagner, S., Berres, M.‐L., Henkel, C., Grötzinger, J., Gressner, A. M., Matern, S., Roeb, E. Inhibition of hepatic fibrogenesis by matrix metalloproteinase‐9 mutants in mice. FASEB J. 20, 444–454 (2006)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Yu, Q., & Stamenkovic, I. (2000) · Genes & Development · doi:10.1101/gad.14.2.163 · Cited by 1,754
Strategies for MMP inhibition in cancer: innovations for the post-trial era
Overall, C. M., & López-Otín, C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc884 · Cited by 1,349 · cited 1×
“However, MMP activity is a crucial target in the therapy of cancer growth and metastasis (52), particularly of hepatocellular carcinoma invasion (53).”
BackgroundIredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075 · cited 2×
“Histological findings from patients with liver fibrosis and from animal models of fibrosis indicate that recovery from liver fibrosis with diminution of excess ECM proteins is possible (3, 19, 20).”
BackgroundMechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1.
Gomis-R¨th, F.-X., Maskos, K., Betz, M., Bergner, A., Huber, R., Suzuki, K., Yoshida, N., Nagase, H., Brew, K., Bourenkov, G. P., et al. (1997) · Nature · doi:10.1038/37995 · Cited by 619 · cited 1×
“The structure of MMP-3 in complex with TIMP-1 (37) (pdb code: 1UEA) was used as template to build a 3-dimensional model of the MMP-9/TIMP-1 complex.”
MethodMurphy, F. R., Issa, R., Zhou, X., Ratnarajah, S., Arthur, M. J. P., Benyon, C., Iredale, J. P., & Nagase, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111490200 · Cited by 432
Iredale, J. P., Benyon, R. C., Arthur, M. J., Ferris, W. F., Alcolado, R., Winwood, P. J., Clark, N., & Murphy, G. (1996) · Hepatology · doi:10.1002/hep.510240129 · Cited by 324
A new hepatocyte stimulating factor: cardiotrophin‐1 (CT‐1)
Peters, M., Roeb, E., Pennica, D., zum Büschenfelde, K.-H. M., & Rose-John, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00972-c · Cited by 39
Self-citation
Cited by
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Liver fibrosis and repair: Immune regulation of wound healing in a solid organ
Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3623 · Cited by 1,310
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ
Iredale, J. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30542 · Cited by 866
Hemmann, S., Graf, J., Roderfeld, M., & Roeb, E. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.003 · Cited by 509
Self-citationThe tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets
Yang, J. D., Nakamura, I., & Roberts, L. R. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.007 · Cited by 390
Metadata
- Authors
- Roderfeld, M., Weiskirchen, R., Wagner, S., Berres, M., Henkel, C., Grötzinger, J., Gressner, A. M., Matern, S., & Roeb, E.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2006-03
- Volume
- 20
- Issue
- 3
- Pages
- 444-454
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2056703234
- Cited by
- 133
- References
- 8
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of hepatic fibrogenesis by matrix metalloproteinase‐9 mutants in mice. https://app.cochat.ai/papers/10.1096/fj.05-4828com
- The paper
- Roderfeld, M., Weiskirchen, R., Wagner, S., Berres, M., Henkel, C., Grötzinger, J., Gressner, A. M., Matern, S., & Roeb, E. (2006). Inhibition of hepatic fibrogenesis by matrix metalloproteinase‐9 mutants in mice. The FASEB Journal. https://doi.org/10.1096/fj.05-4828com
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.